Overview

PRevention Using EPA Against coloREctal Cancer

Status:
Recruiting

Trial end date:
2022-10-31

Target enrollment:

Participant gender:

Summary

This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma. - The name of the study drug involved in this study is: -- AMR101 (VASCEPA).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

National Institutes of Health (NIH)

Treatments:

Eicosapentaenoic acid ethyl ester